NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
Clinical Trials
9 trialsNCT04015739 2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT02022917 2021-01-27
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Chang Gung Memorial Hospital
Phase 2 Completed
NCT01832415 2016-03-17
ENCOURAGE
ARCAGY/ GINECO GROUP
Completed
NCT01202890 2014-01-08
Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT00583622 2013-05-21
Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00407563 2012-04-05
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Accelerated Community Oncology Research Network
Phase 2 Completed